Medical News / AAAAI Congress 2021: Omalizumab Improves Sleep Outcomes with Nasal Polyposis Over 76 Weeks

Omalizumab (Xolair) benefitted sleep disturbance among patients with nasal polyposis over a span of 76 weeks, according to new data presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 Virtual Sessions this week. The research, supported by Novartis Pharmaceuticals and led by Eli O. Meltzer, MD, of the University of California, San Diego, assessed outcomes from the POLYP 1 and POLYP 2 trials which observed the monoclonal antibody plus background corticosteroids versus placebo in randomized patients with chronic rhinosinusitis with nasal polyps (CRSwNP) through 24 weeks. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

MORE MEDICAL NEWS
As covered by Lakiea Wright, MD, in a previous interview segment with HCPLive® during the American ... read more
A collection of articles published at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 ... read more
At the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 Virtual Sessions this weekend, a ... read more
New research shows a recently revised diagnostic criteria is sufficient for emergency departments to identify and ... read more